Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of “Moderate Buy” by Analysts

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) have been given an average rating of “Moderate Buy” by the five analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.50.

Several equities research analysts recently weighed in on ACHV shares. Citigroup started coverage on Achieve Life Sciences in a research note on Tuesday. They issued an “outperform” rating on the stock. Citizens Jmp initiated coverage on shares of Achieve Life Sciences in a report on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 target price on the stock. HC Wainwright began coverage on shares of Achieve Life Sciences in a research report on Thursday, August 21st. They issued a “buy” rating and a $12.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, November 24th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Achieve Life Sciences in a research note on Monday, November 24th.

Insider Transactions at Achieve Life Sciences

In other Achieve Life Sciences news, insider Jaime Xinos sold 20,854 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $2.77, for a total value of $57,765.58. Following the sale, the insider directly owned 74,432 shares of the company’s stock, valued at approximately $206,176.64. The trade was a 21.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Mark K. Oki sold 50,060 shares of the stock in a transaction on Thursday, September 18th. The stock was sold at an average price of $2.92, for a total value of $146,175.20. Following the completion of the sale, the chief financial officer directly owned 127,940 shares in the company, valued at approximately $373,584.80. This represents a 28.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 381,972 shares of company stock worth $1,084,997. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Achieve Life Sciences

A number of hedge funds have recently bought and sold shares of ACHV. Bank of America Corp DE increased its stake in Achieve Life Sciences by 40.6% during the 3rd quarter. Bank of America Corp DE now owns 47,409 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 13,678 shares in the last quarter. Raymond James Financial Inc. lifted its stake in shares of Achieve Life Sciences by 54.7% in the third quarter. Raymond James Financial Inc. now owns 456,372 shares of the biopharmaceutical company’s stock worth $1,438,000 after buying an additional 161,314 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Achieve Life Sciences by 10.7% during the third quarter. ADAR1 Capital Management LLC now owns 47,800 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 4,627 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Achieve Life Sciences during the third quarter valued at approximately $1,383,000. Finally, Squarepoint Ops LLC raised its holdings in Achieve Life Sciences by 2,676.5% in the 3rd quarter. Squarepoint Ops LLC now owns 373,079 shares of the biopharmaceutical company’s stock worth $1,175,000 after acquiring an additional 359,642 shares during the last quarter. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Trading Up 1.1%

Shares of ACHV opened at $4.90 on Tuesday. Achieve Life Sciences has a 1-year low of $1.84 and a 1-year high of $5.78. The company has a current ratio of 6.64, a quick ratio of 6.64 and a debt-to-equity ratio of 0.21. The firm’s 50-day moving average price is $4.10 and its 200-day moving average price is $3.33. The firm has a market capitalization of $260.58 million, a price-to-earnings ratio of -3.35 and a beta of 1.62.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). Sell-side analysts anticipate that Achieve Life Sciences will post -1.17 EPS for the current year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.